Active substance
Ceftazidime
- SFDA 22
- US FDA 18
- Health Canada 6
- US price lines 1
- WHO EML 1
- Safety 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Ceftazidime Venus | 1 g | Powder for solution for injection/infusion · Intramuscular and intravenous use | 1 Vial | SAR 41.65 | Generic · Prescription | VENUS REMEDIES LIMITED | Valid |
| FORTA-Z 1 g powder for solution for injection | 1 g | powder for solution for injection · Parenteral use | 1 Vial | SAR 38.95 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Fetazim | 1 g | powder for solution for injection · Intramuscular and intravenous use | 1 Vial | SAR 21.35 | Generic · Prescription | PHARMA INTERNATIONAL CO | Valid |
| Fetazim | 2 g | powder for solution for injection · Intravenous use | 1 Vial | SAR 42.60 | Generic · Prescription | PHARMA INTERNATIONAL CO | Valid |
| Loftaz | 1 g | Powder for solution for injection/infusion · Intramuscular and intravenous use | 1 Vial | SAR 38.95 | Generic · Prescription | SAUDI PHARMACEUTICAL INDUSTRIES | Valid |
| NEGACEF 1GM VIAL | 1 g | Powder for injection · Intravenous use | 1 Vial | SAR 43.30 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| NEGACEF 2GM Injection | 2 g | Injection · Intravenous use | 1 Vial | SAR 69.95 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| ZIDIME 1GM GLASS VIAL IV-IM | 1 g | Powder for injection · Intravenous use | 1 Vial | SAR 51.55 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| ZIDIME 2GM I.V INJ | 2 g | Powder for injection · Intravenous use | 1 Vial | SAR 95.40 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| FORTUM 1 g | 1 g | Powder for injection · Intravenous use | 5 Vial | SAR 238.75 | Generic · Prescription | GLAXO SAUDI ARABIA | Withdrawn by MAH · Not Marketed |
| FORTUM 1 g Powder for injection | 1 g | Powder for injection · Intravenous use | 1 Vial | SAR 37.20 | Generic · Prescription | GLAXO SAUDI ARABIA | Withdrawn by MAH · Not Marketed |
| FORTUM 2 g | 2 g | Powder for injection · Intravenous use | 5 Vial | SAR 477.55 | Generic · Prescription | GLAXO SAUDI ARABIA | Withdrawn by MAH · Not Marketed |
| FORTUM 2 g | 2 g | Powder for injection · Intravenous use | 1 Vial | SAR 86.15 | Generic · Prescription | GLAXO SAUDI ARABIA | Withdrawn by MAH · Not Marketed |
| FORTUM 500 mg | 500 mg | Powder for injection · Intravenous use | 1 Vial | SAR 29.95 | NCE · Prescription | GLAXO SAUDI ARABIA | Withdrawn by MAH · Not Marketed |
| FORTUM 500 mg | 500 mg | Powder for injection · Intravenous use | 5 Vial | SAR 124.75 | NCE · Prescription | GLAXO SAUDI ARABIA | Withdrawn by MAH · Not Marketed |
| KEFADIM INJ 1G VIAL | 1 g | Injection · Intravenous use | 25 Vial | SAR 1074.35 | NCE · Prescription | Eli Lilly and Company | Withdrawn by MAH · Not Marketed |
| KEFADIM INJ 2G VIAL | 2 g | Injection · Intravenous use | 10 Vial | SAR 859.50 | NCE · Prescription | Eli Lilly and Company | Withdrawn by MAH · Not Marketed |
| NEGACEF 0.5 g INJ. | 500 mg | Powder for injection · Intravenous use | 1 Vial | SAR 24.70 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| PARZIDIME 0.5 GM POWDER FOR SOLUTION FOR Injection* | 500 mg | Injection · Intravenous use | 1 Vial | SAR 9.65 | Generic · Prescription | SANDOZ | Withdrawn by MAH · Not Marketed |
| PARZIDIME 1 GM POWDER FOR SOLUTION FOR Injection* | 1 g | powder for solution for injection · Intravenous use | 1 Vial | SAR 17.95 | Generic · Prescription | SANDOZ | Withdrawn by MAH · Not Marketed |
| ZIDACEF 1000 MG VIAL I.M - I.V Injection* | 1 g | Injection · Intravenous use | 1 Vial | SAR 19.95 | Generic · Prescription | SHIFA PHARMACEUTICAL INDUSTRIES | Invalid · Not Marketed |
| ZIDACEF 500 MG VIAL I.M - I.V Injection* | 500 mg | Injection · Intravenous use | 1 Vial | SAR 10.70 | Generic · Prescription | SHIFA PHARMACEUTICAL INDUSTRIES | Invalid · Not Marketed |
Indications — CHI Daman Drug Formulary
Pyogenic Arthritis; Septic Shock
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CEFTAZIDIME | 1GM/VIAL; 2GM/VIAL; 6GM/VIAL | injectable · injection | ACS DOBFAR | Prescription | 20 Nov 1985 |
| TAZICEF | 1GM/VIAL; 2GM/VIAL; 6GM/VIAL | injectable · injection | HOSPIRA | Prescription | 6 Mar 1986 |
| TAZICEF | 1GM/VIAL; 2GM/VIAL | injectable · injection | HOSPIRA | Prescription | 31 Oct 1993 |
| FORTAZ | 500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 1GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 2GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 6GM/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | PAI HOLDINGS PHARM | Discontinued | 19 Jul 1985 |
| CEFTAZIDIME | 500MG/VIAL | injectable · injection | ACS DOBFAR | Discontinued | 20 Nov 1985 |
| TAZIDIME | 1GM/VIAL; 2GM/VIAL | injectable · injection | LILLY | Discontinued | 20 Nov 1985 |
| TAZICEF | 500MG/VIAL | injectable · injection | HOSPIRA | Discontinued | 6 Mar 1986 |
| TAZIDIME IN PLASTIC CONTAINER | 1GM/VIAL; 2GM/VIAL | injectable · injection | LILLY | Discontinued | 10 Jul 1986 |
| FORTAZ IN PLASTIC CONTAINER | EQ 10MG BASE/ML; EQ 20MG BASE/ML; EQ 40MG BASE/ML | injectable · injection | PAI HOLDINGS PHARM | Discontinued | 28 Apr 1989 |
| CEPTAZ | 500MG/VIAL; 1GM/VIAL; 2GM/VIAL; 10GM/VIAL | injectable · injection | GLAXOSMITHKLINE | Discontinued | 27 Sep 1990 |
| CEFTAZIDIME SODIUM IN PLASTIC CONTAINER | EQ 10MG BASE/ML; EQ 20MG BASE/ML; EQ 40MG BASE/ML | injectable · injection | BAXTER HLTHCARE | Discontinued | 29 Apr 1993 |
| CEFTAZIDIME | 1GM/VIAL | injectable · injection | WOCKHARDT | Discontinued | 15 Oct 2008 |
| CEFTAZIDIME | 500MG/VIAL; 1GM/VIAL; 2GM/VIAL | injectable · injection | AUROBINDO PHARMA LTD | Discontinued | 28 May 2010 |
| CEFTAZIDIME | 6GM/VIAL | injectable · injection | AUROBINDO PHARMA LTD | Discontinued | 28 May 2010 |
| CEFTAZIDIME IN DEXTROSE CONTAINER | EQ 1GM BASE; EQ 2GM BASE | injectable · injection | B BRAUN | Discontinued | 13 Jun 2011 |
| PENTACEF | 1GM/VIAL; 2GM/VIAL | injectable · injection | GLAXOSMITHKLINE | Discontinued | |
| PENTACEF | 1GM/VIAL; 2GM/VIAL | injectable · injection | GLAXOSMITHKLINE | Discontinued | |
| PENTACEF | 6GM/VIAL; 10GM/VIAL | injectable · injection | GLAXOSMITHKLINE | Discontinued |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| CEFTAZIDIME FOR INJECTION BP | 02437848 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | STERIMAX INC |
| CEFTAZIDIME FOR INJECTION BP | 02437856 | 2 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | STERIMAX INC |
| CEFTAZIDIME FOR INJECTION BP | 02437864 | 6 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | STERIMAX INC |
| CEFTAZIDIME FOR INJECTION, USP | 00886955 | 2 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| CEFTAZIDIME FOR INJECTION, USP | 00886963 | 6 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| CEFTAZIDIME FOR INJECTION, USP | 00886971 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR; INTRAVENOUS | FRESENIUS KABI CANADA LTD |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CEFTAZIDIME 1 GM VIAL | $3.70448 | per EA | 17 Dec 2025 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.2.2. Watch group antibiotics · complementary
First choice: Endophthalmitis; Pseudomonas aeruginosa resistant to other antibiotic
Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection
Safety signals and safety-related labeling changes
- US FDA 28 Feb 2025 AVYCAZ — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 20 Oct 2021 CEFTAZIDIME IN DEXTROSE CONTAINER — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 28 Jul 2017 FORTAZ — safety-related labeling change
Labeling sections changed: Warnings and Precautions - US FDA 28 Jul 2017 FORTAZ IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Warnings and Precautions
Combinations containing Ceftazidime
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.